Aug 2026· ecancermedicalscience· 0 citations· 32 references
TL;DR
It is shown that the survival of patients with metastatic BC in Armenia is poor, with an mOS just surpassing 1 year, and it is believed that the implementation of newer drugs, like immunotherapy and antibody-drug conjugates, may improve outcomes.
Abstract
Bladder cancer (BC) is the fifth most common cancer by incidence in Armenia, with 500– 550 new cases diagnosed every year. For this retrospective hospital-based study, we collected data during the period 01 January 2010–01 January 2023 from three main oncology centres in Armenia: ‘Yeolyan Hematology and Oncology Center’, ‘Mikaelyan Institute of Surgery’ and “Muratsan” Hospital Complex of Yerevan State Medical University. Statistical analysis was conducted on 01 November 2023. Eighty-seven patients with BC treated during the mentioned period in these three hospitals were included in the final analysis. The male-to-female ratio was 8.6:1. Median age at diagnosis was 65 years. About 5.7% of patients had stage I, 17.2% stage II, 47.1% stage III, 25.3% stage IV BC and for 4.6% of patients, the stage was unknown. Among stage IV patients, the most common metastasis sites were lungs (36.4%), followed by non-regional lymph nodes (31.8%). Median overall survival (mOS) was 31 months for the entire cohort. An mOS was 62 months for stage II, 40 months for stage III and 14 months for stage IV patients. While overall survival for stages II–III, BC was higher than for the metastatic stage; this difference was not statistically significant (40 versus 14 months; p = 0.11). Around 61% of patients received first-line chemotherapy with cisplatin and 33.3% with carboplatin. In people with stage II–III BC, an mOS was significantly better for those treated with cisplatin-containing regimens, compared with those treated with carboplatin-containing regimens (40 versus 16 months; p = 0.021), while in stage IV, this difference was not statistically significant (30 versus 14 months; p = 0.269). In conclusion, this retrospective study with a relatively small number of patients has shown that the survival of patients with metastatic BC in Armenia is poor, with an mOS just surpassing 1 year. We believe that the implementation of newer drugs, like immunotherapy and antibody-drug conjugates, may improve outcomes.
Background: Colon cancer is the fourth most commonly diagnosed cancer worldwide, with elderly individuals accounting for nearly one-third of new cases. While adjuvant chemotherapy has been associated with improved survival outcomes; its effectiveness in elderly patients remains unclear. This retrospective study was conducted to assess the efficacy of adjuvant chemotherapy in elderly patients with stage 3 colon cancer.
Methods: We identified all patients aged 70 years or older with stage 3 colon cancer who were treated and followed at King Hussein Cancer Center (KHCC) in Amman, Jordan between 2015 and 2020. Intramural KHCC funding was granted for MMR testing in patients who received adjuvant chemotherapy. Descriptive and survival analyses were performed in JASP 0.95.4 software.
Results: A total of 66 patients were included. The median age at diagnosis was 73 years, and 39.3% were females. 74.2% had T3 tumors, and 69.6% had N1 disease. Adjuvant chemotherapy was administered to 71.2% (n=47) of patients, including 14 with deficient MMR status. Five-year overall survival (OS) favored patients treated with adjuvant chemotherapy compared with those who did not, although the difference was not statistically significant (80.3% vs 71.9%; HR 0.71, 95% CI 0.23–2.16; P = 0.538). Among patients treated with adjuvant chemotherapy, 5-year OS was 83.4% with Oxaliplatin-doublet therapy versus 70.7% with single-agent 5-FU based therapy (HR 0.59, 95% CI 0.14-2.44; P = 0.460). Additionally, there was no significant OS difference observed between different chemotherapy regimens after stratification by MMR status (P = 0.271).
Conclusions: In this single-center cohort, adjuvant chemotherapy demonstrated a non-significant trend toward improved overall survival among elderly patients with stage III colon cancer; however, interpretation was limited by the small sample size.
Yacob Saleh, Suhaib Khater, T. Alawabdeh et al.· Jordan Medical Journal· 0 citations
Findings highlight the importance of considering clinical and pathological features in the management and prognosis of RCC patients and highlight the importance of considering clinical and pathological features in the management and prognosis of patients diagnosed with malignant renal tumors.
Mohammad Sadri, S. Masudi, S. Farshid et al.· Caspian Journal of Internal...· 0 citations
BLABEL was set up to collect data on the first-line treatment patterns and 5-year disease-evolution of non-muscle invasive bladder cancer (NMIBC) in Belgium. The primary objective was to describe treatment regimens following diagnosis, with patient and disease characteristics and 5-year disease evolution as secondary objectives. This retrospective chart review included 232 NMIBC patients diagnosed (Ta, T1, Tis) between January 1, 2016, and December 31, 2017, across eight centres. At diagnosis, 86.6% (N = 201) had Ta/T1 disease without carcinoma in situ (CIS). After transurethral resection of the tumour, 42.2% of all patients were monitored through observation after TURB, 44.4% received Bacillus Calmette-Guérin (BCG) instillations and 10.8% received intravesical chemotherapy. 90.9% had a complete response (CR) to their initial treatment. During the 5-year follow-up 28.4% experienced NMIBC recurrence, 7.3% progressed to muscle-invasive bladder cancer (MIBC), 3% to metastatic disease and 3% died due to bladder cancer. At 5 years, 65.5% remained disease-free, indicating that 34.5% experienced some form of recurrence. Among CIS patients, 77.4% had an initial CR, 29% experienced NMIBC recurrence and 12.9% progressed to MIBC. This Belgian real‑world study provides insight into first‑line treatment patterns and long‑term outcomes of NMIBC following diagnosis. Most patients underwent observation or BCG instillations after TURB. While the initial response to intravesical treatment is high, approximately one-third of patients recurred within 5 years. High-risk NMIBC patients, particularly those with CIS, had worse outcomes, demonstrating an unmet need.
Y. Raskin, F. Baekelandt, K. Decaestecker et al.· World journal of urology· 0 citations
Despite late-stage presentation typical of low- and middle-income countries, survival outcomes were broadly consistent with international real-world data and highlights the urgent need for improved screening programmes.
A. Tadevosyan, Gagik Jilavyan, Evelina Bakhshinyan et al.· South Asian Journal of Cance...· 0 citations
Purpose of the study
. To evaluate treatment outcomes in patients with stage III–IV colon cancer residing in the Southern Federal District of the Russian Federation.
Patients and method
s. A retrospective analysis was performed of the medical records of 200 patients with stage III–IV colon cancer who underwent treatment and follow-up at the National Medical Research Centre for Oncology between 2019 and 2024. Overall survival (OS) was assessed, as well as its association with sex, disease stage, primary tumor location, KRAS, NRAS, and BRAF mutation status, tumor microsatellite instability (MSI) status, and antitumor treatment strategy.
Results
. The median follow-up from the time of presentation to the National Medical Research Centre for Oncology was 1.4 years. The 5‑year OS rate was 31 %, with a median overall survival of 3.4 years. The 5‑year OS rate was significantly associated with disease stage, reaching 46 % in patients with stage III disease and 18 % in those with stage IV disease (p = 0.00005). The presence of KRAS mutations (3‑year OS: 53 % in the wild-type group vs. 28 % in the mutant group), BRAF mutations (42.5 % vs. 18 %, respectively), and MSI status (67 % for MSI tumors vs. 42.5 % for microsatellite-stable [MSS] tumors) significantly influenced survival outcomes. Among patients with stage IV disease, survival was also associated with the type of targeted therapy administered. Improved survival was observed in patients receiving combined inhibition of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) compared with VEGF inhibitor-based therapy alone. The 3‑year OS rate was 66 % (median OS, 4.1 years) in the combined EGFR/VEGF inhibition group versus 31 % (median OS, 2.1 years) in the VEGF inhibitor group.
Conclusion
. Nearly half of all colon cancer cases (47.6 %) were diagnosed at advanced stages, which are associated with an unfavorable prognosis, particularly in tumors harboring pathogenic mutations and exhibiting a microsatellite-stable phenotype. These findings underscore the importance of genetically and epigenetically guided therapeutic approaches aimed at identifying novel therapeutic targets and developing more effective treatment strategies.
O. Kit, I. Mironenko, E. Dzhenkova et al.· South Russian Journal of Can...· 0 citations
Introduction: Breast cancer in young women represents an emerging public health concern. Its impact is often poorly understood and underestimated.
Objectives: This study aimed to investigate the diagnostic and prognostic aspects of breast cancer in women aged 40 years or younger who were treated at the Regional Hospital Center of Thiès.
Patients and Methods: This retrospective cross-sectional study was conducted from January 5, 2017, to June 8, 2023. It included 101 women aged 40 years or younger with histologically confirmed breast cancer who received care at the Regional Hospital Center of Thiès.
Results: The mean age of the patients was 34 years, and the mean delay to consultation was 10.53 months. The disease was predominantly locally advanced: 56.4% of patients had T4 disease, 73.3% had lymph node involvement, and 24.75% had metastases at diagnosis. Invasive ductal carcinoma of no special type was the most frequent histological type, accounting for 96.04% of cases, and SBR grade II was observed in 62.4%. Immunohistochemistry identified luminal B disease in six patients (5.94%) and triple-negative disease in four (3.96%). All patients received chemotherapy; 89.11% received neoadjuvant chemotherapy and 7.9% received adjuvant chemotherapy. Surgery was performed in 44 patients (43.56%). Radiotherapy was administered to 14 patients (13.86%), and hormone therapy was indicated for nine patients (8.9%). Thirty patients had died by the end of the study. Overall survival was 65.6% at 3 years and 60.1% at 5 years.
Conclusion: Breast cancer is increasingly prevalent among young women and presents with a more aggressive profile and a poorer prognosis than in older women. Management remains challenging and may be complicated by diagnostic delays, poor therapeutic adherence, and a persistently low survival rate.
K. Fall, L. Gueye, N. Faye et al.· Asian Journal of Advanced Re...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
